Phase 2 Lymphoma Trial, Recruiting NCT06697184 Sponsor: BeOne Medicines Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06697184
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are generally able to carry out some daily activities and are not completely disabled (your doctor will assess this using a standard scale)
  • Your main organs (such as kidneys, liver, and heart) are working well enough, and you have not had a recent blood transfusion or injections to boost blood cell counts
  • If you are able to become pregnant, you must be willing to use a highly reliable form of contraception and avoid donating eggs during the study and for at least 7 days after the last dose of one study drug, or 1 month after the last dose of the other, whichever comes later

If you have Chronic Lymphocytic Leukemia (CLL):

  • You have a confirmed diagnosis of CLL and your doctor has determined that your disease now needs treatment based on specific features
  • You have at least one area of disease that can be measured on a CT or MRI scan, and you have never had certain transformations of your CLL into a more aggressive form

If you have Mantle Cell Lymphoma (MCL):

  • You have a confirmed diagnosis of MCL based on recognised international medical classifications
  • Your lymphoma has come back or stopped responding to your most recent treatment, and you have had at least one previous course of treatment (confirm with trial site regarding specific rules about a type of previous therapy called BTKi)
  • You have at least one tumour that is large enough to be measured on a scan

Who may not be able to join:

  • You are unable or unwilling to follow the requirements of the trial
  • You currently have an active hepatitis B or hepatitis C infection
  • You have tested positive for HIV, unless certain specific conditions are met (confirm with trial site)
  • You have had a major surgical procedure within the last 28 days before starting the trial treatment
  • You have previously received systemic (whole-body) treatment for CLL
  • You have an uncontrolled condition where your immune system attacks your own blood cells, and it requires treatment
  • You have previously taken a type of drug called a BCL-2 inhibitor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Study Director, BeOne Medicines

Phone: 1.877.828.5568

Australian sites

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales
Genesiscare St Andrews, Adelaide, South Australia
Cabrini Hospital Malvern, Malvern, Victoria
The Alfred Hospital, Melbourne, Victoria
Rockingham Hospital, Cooloongup, Western Australia
Linear Clinical Research, Nedlands, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
BeOne Medicines
Registry
ClinicalTrials.gov
Start date
23 January 2025
Est. completion
30 November 2029

Where this trial is recruiting

🇦🇺 Australia 🇫🇷 France 🇬🇧 United Kingdom 🇺🇸 United States

6 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants who Experience Tumor Lysis Syndrome (TLS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov